Optimal strategies for antigen-specific melanoma vaccination are currently being defined in experimental mouse models. Using a single H2-K b -binding peptide epitope derived from the melanosomal enzyme tyrosinase-related protein 2 (TRP2) in C57BL/6 mice, we show that adenovirus-transduced dendritic cells (DC) are clearly superior to peptide-pulsed DC for the induction of CD8 þ T cells and antimelanoma immunity. Vaccine efficacy strictly depended on the presence of linked CD4 þ T-cell help during the priming but not the effector phase of the immune response. These results provide important information for the translation of melanoma vaccine strategy in future clinical applications.
Introduction
Genetic immunization strategies have become attractive for the development of melanoma vaccines, because a number of antigens recognized by cellular components of the immune system have been identified at the molecular level in melanoma patients. 1, 2 These melanoma antigens include normal cellular proteins such as the tyrosinase family of enzymes involved in melanin synthesis, which are endogenously expressed in melanocytes and melanoma cells. 3, 4 However, it has become clear that mechanisms maintaining peripheral tolerance to melanocytic selfantigens present a major obstacle for the development of antigen-specific melanoma vaccines. [5] [6] [7] A number of strategies have been suggested to circumvent tolerance and induce effective antimelanoma immunity such as the adjuvant use of cultured dendritic cells (DC) or the coadministration of immunoenhancing molecules. [8] [9] [10] [11] [12] [13] [14] [15] Optimal vaccination protocols need to be identified in adequate preclinical models in order to successfully transfer the idea of antigen-specific tumor immunotherapy using genetic immunization in the clinical setting for the treatment of patients with melanoma.
Using the melanosomal enzyme tyrosinase-related protein 2 (TRP2) expressed by melanocytes and most melanoma cells as a model self-antigen in C57BL/6 mice, we previously showed that genetic immunization using a recombinant adenovirus (Ad) encoding murine TRP2 was not able to stimulate strong antimelanoma immunity, unless cultured DC were used as a biological adjuvant. 9 Efficacy of Ad-transduced DC was dependent on the presence of CD4 þ T-helper cells. 10 As an alternative strategy, we found that genetic immunization with a recombinant Adenovirus encoding murine TRP2 linked to an immunogenic helper protein such as the enhanced green fluorescent protein (EGFP) was also able to induce protective antimelanoma immunity. 15 CD4 þ T-helper cells are currently thought to promote CD8 þ T-cell immunity by 'licensing' DC via CD40-CD40 ligand interactions. [16] [17] [18] [19] In the present paper, we study the cellular and molecular regulation of tolerance and immunity of melanocyte-specific CD8 þ T cells in greater detail. We show that genetic immunization with cultured DC targeting a single CTL-defined H2-K b -binding peptide TRP2 aa180-188 is able to mediate protective immunity against B16 melanoma cells. Importantly, Ad-transduced DC were superior to peptide-pulsed DC. Experiments in CD4 knockout mice and with depleting anti-CD4 mAb indicated that CD4 þ T-cell help is required for effective stimulation and expansion of TRP2 aa180-188 -specific CD8 þ T cells, but is dispensable in the effector phase of protective tumor immune defense.
Materials and methods
Animals and cell lines C57BL/6 wild-type and C57BL/6 CD4 knockout mice (H-2 b ), 6-12 week old, were bred at the Central Animal Facility of the University of Bonn. C57BL/6 wild-type mice were purchased from Charles Rivers (Sulzfeld, Germany) and C57BL/6 CD4 knockout mice were purchased from The Jackson Laboratory (Maine). All animal experiments were approved by local governmental authorities and performed according to institutional guidelines for the care and use of laboratory animals. B16-F1 (H-2 b ) is a spontaneous murine melanoma and was maintained in DMEM supplemented with 10% heatinactivated FCS, 2 mM L-glutamine, 50 mM 2-mercaptoethanol, 100 IU/ml penicillin, and 100 mg/ml streptomycin (all reagents were from Gibco, Karlsruhe, Germany).
Peptides and monoclonal antibodies
The H-2K b -binding peptide SVYDFFVWL (TRP2 aa180-188 ) derived from the murine melanosomal protein TRP2, 20 the H-2K b -binding peptide ICPMYARV (bgal aa497-504 ) derived from Escherichia coli b-galactosidase, 21 and the H-2K b -binding peptide SIINFEKL (OVA aa257-264 ) derived from chicken ovalbumin were purchased from GENOSPHERE (Paris, France). Peptides were dissolved at 10 mg/ml in PBS containing 10% DMSO and stored at À201C. Ascites containing the anti-CD4 mAbs was prepared commercially (Eurogentec, Belgium) using the hybridoma cell line GK1.5 (TIB 207, Promochem (ATCC), Wesel, Germany). Purified control rat IgG was purchased from Sigma-Aldrich (Germany) and dissolved at 1 mg/ml in PBS.
Recombinant Adenovirus
Adenoviral shuttle plasmids expressing the fusion proteins EGFP.TRP2 aa180-188 and EGFP.OVA aa257-264 were constructed using standard PCR techniques. Expression of EGFP was confirmed in transiently transfected 293 cells by fluorescence microscopy and the size of the fusion proteins was verified by Western blot analyses with EGFP-specific rabbit antiserum. Plasmids were grown in E. coli strain DH5a and purified using the Qiagen Plasmid Maxi Kits (Qiagen, Hilden, Germany). E1-and E3deleted adenoviral vectors expressing the fusion proteins were generated through Cre-lox recombination with reagents generously provided by Dr S Hardy (Somatix, Alameda, CA). 22 Adenovirus were propagated on 293 cells, purified by cesium chloride density gradient centrifugation and subsequent dialysis according to standard protocols, and stored at À701C. New Adenovirus were quantified by optical absorbance. The number of particles was calculated according to the following formula: OD 260 Â dilution-factor Â 10 12 ¼ particle/ml. A total of 100 particles were considered to be equivalent to 1 PFU. All vectors express only the antigen of interest under the CMV immediate-early promoter.
Culture, adenoviral transduction, and peptide loading of DC Murine DC were generated from bone marrow precursors as described previously. 10 Briefly, bone marrow cells were harvested from femurs and tibias, depleted of red blood cells, and washed twice in PBS. Cells were resuspended in DC medium consisting of RPMI 1640 supplemented with 10% heat-inactivated FCS, 1000 U/ml each of recombinant murine GM-CSF and IL-4 (a kind gift of Schering-Plough Research Institute, Kenilworth, NJ), 2 mM L-glutamine, 1 mM sodium pyruvate, 0.1 mM nonessential amino acids, 0.1 mM HEPES, 50 mM 2-ME, 100 IU/ml penicillin, and 100 mg/ml streptomycin and cultured (371C, 5% CO 2 ) in six-well plates at 1 Â 10 6 cells/ 3 ml/well. All cell culture reagents were purchased from Gibco (Karlsruhe, Germany). Cells were fed with fresh medium containing GM-CSF and IL-4 after 2 days. Loosely adherent DC were harvested after 5 days for transduction with recombinant Ad, washed twice with PBS, and distributed at 10 6 cells/300 ml/well of a 24-well plate in DC medium without serum. Transduction with recombinant Adenovirus was performed at an MOI of 250 (i.e. 2.5 Â 10 8 PFU/well). Cells were incubated for 4 h at 371C and 5% CO 2 . After this, 1.5 ml of DC medium with 10% FCS was added. The transduction efficiency of the DC was determined by flow cytometry and ranged between 20 and 40%. Alternatively, DC were pulsed on day 7 with 1 mg/ml of synthetic peptide for 1 h. 23 DC were routinely used for immunization on day 7 (48 h after transduction and directly after peptide pulsing). Tumor protection assays and depletion of CD4 þ T lymphocytes The induction of antitumor immunity was assessed 1-2 weeks after immunization. Mice were challenged by i.v. injection of 4 Â 10 5 B16 melanoma cells, which experimentally induces heavily pigmented lung metastases. The number of macroscopically visible metastases on the surface of the lungs was routinely counted with the help of a dissecting microscope 14 days after challenge. Depletion of CD4 þ T cells was performed by intraperitoneal injections of 200 ml of anti-CD4 ascites fluid or 100 mg of purified rat IgG as control on days À2, À1, þ 5, þ 9, and þ 12 with respect to the day of tumor challenge.
Genetic immunization of mice

Flow cytometric analyses
Splenocytes from immunized mice were stained with PE-labeled H2-K b -OVA aa257-264 pentamers (ProImmune, Oxford, UK) along with tricolor-labeled anti-CD8 mAb (Pharmingen, Germany). Data acquisition and analysis was performed using a Becton Dickinson FACSCalibur with CELLQuest software (Becton Dickinson, Heidelberg, Germany).
In vivo cytotoxicity assay Naı¨ve syngenic splenocytes were pulsed with 1 mg/ml of the OVA (SIINFEKL) peptide for 15 min at 371C and subsequently labeled with 1.5 mM CFSE (CFSE high) for 15 min at 371C. Unpulsed splenocytes were labeled with 0.15 mM CFSE (CFSE low) for 15 min at 371C and served as an internal control. Cells were washed and mixed at a 1:1 ratio. A total of 10 7 cells were injected i.v. into previously immunized mice. After 4 h, splenocytes from a single mouse were analyzed by FACS to detect the presence of CFSE-labeled cells. To calculate specific lysis, the following formula was used: ratio ¼ (percentage CFSE high /CFSE low ). Percentage specific lysis ¼ 100À
Statistical analyses
The significance of differences in the number of lung metastases was assessed with the nonparametric Mann-Whitney U-test utilizing the SPSS 11 computer program. The difference between groups was considered statistically significant when the P-value was lower than 0.05 and highly significant when the P-value was lower than 0.01.
Results
Melanoma vaccination with peptide-pulsed DC
To assess the efficacy of the CTL-defined H2-K b binding epitope TRP2 aa180-188 (SVYDFFVWL) for the induction of antitumor immunity, we initially used TRP2 aa180-188 peptide-pulsed DC. The H2-K b -binding peptide OVA aa257-264 (SIINFEKL) derived from chicken ovalbumin was used as a control antigen. DC were cultured from bone marrow precursors with the help of GM-CSF and IL-4 and loaded on day 7 with 1 mg/ml of synthetic TRP2 aa180-188 or OVA aa257-264 peptide for 1 h. Antigenpulsed DC were washed and groups of five C57Bl/6 mice were immunized by one i.v. injection of 2.5 Â 10 5 peptidepulsed DC. At 2 weeks after immunization, mice were challenged intravenously with 4 Â 10 5 B16 melanoma cells and the number of experimentally induced metastases was counted 14 days later. Injection of TRP2 aa180-188 peptidepulsed DC only reduced the number of lung metastases ( Figure 1 ).
Comparison of peptide-pulsed with Ad-transduced DC for the stimulation of CD8 þ T cells in vivo
We hypothesized that continuous endogenous antigen synthesis is necessary to promote optimal antigenpresentation by DC. Therefore, we constructed a recombinant Ad expressing the peptide OVA aa257-264 (SIINFEKL) attached to the C-terminus of EGFP (Ad-EGFP.OVA aa257-264 ) and comparatively assessed Ad-transduced and peptide-pulsed DC for their ability to stimulate CD8 þ T cells using ovalbumin as a model antigen. Cultured DC were transduced on day 5 as described in Material and methods and used on day 7. C57BL/6 mice were immunized with Ad-EGFP. OVA aa257-264 -transduced or OVA aa257-264 peptide-pulsed DC. Splenocytes were harvested 1 week after immunization and tested for the induction of OVA aa257-264 peptidespecific CD8 þ T cells using H2-K b -OVA aa257-264 pentamers by flow cytometry. As depicted in Figure 2a , the number of H2-K b -OVA aa257-264 pentamer-positive CD8 þ T cells was more than three times higher in mice immunized with Ad-EGFP.OVA aa257-264 -transduced DC than in mice immunized with OVA aa257-264 peptide-pulsed DC. To further analyze the differences between Adtransduced and peptide-pulsed DC, we measured the induction of OVA aa257-264 -specific cytotoxicity in vivo against OVA aa257-264 peptide-pulsed target cells. As shown in Figure 2b , immunization with Ad-EGFP. OVA aa257-264 -transduced DC mediates a stronger in vivo cytotoxicity than immunization with OVA aa257-264 peptide-pulsed DC.
Induction of antimelanoma immunity with Adtransduced DC
In subsequent experiments, we comparatively assessed the ability of Ad-transduced DC and peptide-pulsed DC to stimulate antimelanoma immunity using a recombinant Adenovirus encoding the TRP2 aa180-188 peptide linked to the C-terminus of EGFP (Ad-EGFP.TRP2 aa180-188 ). Groups of five C57BL/6 mice were immunized with Ad-EGFP.TRP2 aa180-188 -or Ad-EGFP.OVA aa257-264 -transduced DC. After 1 week, mice were challenged by i.v. injection of 4 Â 10 5 B16 melanoma cells and the number of lung metastases were evaluated 14 days later. As shown injection of 4 Â 10 5 B16 melanoma cells, which experimentally induces heavily pigmented lung metastases. At 14 days after challenge macroscopically visible metastases on the surface of the lungs were counted. Each dot represents an individual mouse of a single experiment, which was repeated three times with similar results. The difference between groups was considered statistically highly significant when the P-value was lower than 0.01.
in Figure 3 , genetic immunization with Ad-EGFP.TR-P2 aa180-188 -transduced DC was able to promote complete protection against the growth of B16 lung metastases. Thus, genetic immunization targeting a single peptide epitope derived from the melanocytic self-antigen TRP2 is able to provide full protection against metastatic growth of B16 melanoma. Compared with the results presented in Figure 1 , the Ad-EGFP.TRP2 aa180-188 -transduced DC were superior to TRP2 aa180-188 peptide-pulsed DC in mediating antimelanoma immunity.
Influence of adenoviral transduction or EGFP on the efficacy of DC-based vaccination
In principle, adenoviral transduction or expression of EGFP could augment the imunogenicity of cultured DC. To test this possibility, we immunized mice with DC, which were transduced with Ad-EGFP on day 5 as described and subsequently pulsed with the synthetic peptides TRP2 aa180-188 or OVA aa257-264 on day 7.
Immunization with Ad-EGFP-transduced DC pulsed with the TRP2 aa180-188 peptide did not confer stronger protection against experimentally induced B16 lung metastases. Again, the number of lung metastases was only reduced when compared with the control immunized group receiving Ad-EGFP-transduced DC pulsed with the synthetic OVA aa257-264 peptide (Figure 4 ). This result shows that the enhanced efficacy of Ad-EGFP.TR-P2 aa180-188 -transduced DC over TRP2 aa180-188 peptidepulsed DC is not due to adenoviral transduction or the expression of the foreign immunogenic protein EGFP.
Induction of antimelanoma immunity with direct injection of recombinant Adenovirus
Administration of recombinant Adenovirus encoding murine TRP2 with cultured DC is able to circumvent peripheral tolerance and augment the weak immunogenicity of murine TRP2. 9 Our previous studies supported the notion that DC provide CD4 þ T-cell help for the effective induction of TRP2-specific cytotoxic CD8 þ T cells. 10 As an alternative strategy, we demonstrated that CD4 help could be provided by linking murine TRP2 to the foreign immunogenic protein EGFP. 15 As depicted in Figure 5 Ad-EGPF.TRP2 aa180-188 encoding only the TRP2 aa180-188 peptide linked to EGFP was also able to completely prevent growth of B16 melanoma lung metastases and effectively stimulate TRP2 aa180-188 -specific CD8 þ T cells in vivo. This result again demonstrates that genetic immunization targeting a single peptide epitope derived from the melanocytic self-antigen TRP2 is able to mediate protective antimelanoma immunity in this model system.
Role of CD4 þ T-helper cells in the priming and the effector phase
Previously, we reported that the efficacy of genetic immunization with Ad-EGFP.TRP2 was abrogated in CD4 knockout mice. 10, 15 As shown in Figure 6a , this was also true for genetic immunization with Ad-EGFP.TR-P2 aa180-188 encoding only the TRP2 aa180-188 peptide linked to EGFP. However, experiments in CD4 knockout mice do not allow for a distinction between the role of CD4 þ T-helper cells during the priming and the effector phase of the antitumor immune response. To determine the role of CD4 þ T cells in the effector phase, groups of five C57Bl/6 mice were immunized with Ad-EGFP.TRP2 aa180-188 and depleted of CD4 þ T cells by injection of anti-CD4 mAb on days À2, À1, þ 5, þ 9, and þ 12 with respect to the day of tumor challenge. Control groups of mice received purified rat IgG. Almost complete elimination of CD4 þ T cells in vivo was confirmed by flow cytometry (data not shown). Protective antimelanoma immunity was not impaired in mice depleted of CD4 þ T cells after vaccination but before tumor challenge ( Figure 6b ). These results show that CD4 þ T-helper cells were only needed for priming of TRP2-specific CD8 þ T cells, and were not required during the effector phase of the immune response.
Discussion
Recently, the ability to generate large numbers of DC has generated great enthusiasm for the immunotherapy of cancer. 8, [24] [25] [26] A large number of clinical studies utilizing cultured human DC pulsed with CTL-defined, MHCrestricted synthetic melanoma peptides are being tested in patients with metastatic melanoma worldwide. First or Ad-EGFP.OVA aa257-264 . At 1 week after immunization, mice were challenged with 4 Â 10 5 B16 melanoma cells and lung metastases were counted 14 days later. Each dot represents an individual mouse of a single experiment, which was repeated three times with similar results. The difference between groups was considered statistically highly significant when the P-value was lower than 0.01.
published reports provided proof-of-principle for this vaccine strategy using DC. 27, 28 However, clinical results were variable. Notably, long-lasting clinical responses in individual patients were reported in several studies. Clinical responses occasionally coincided with a specific cytotoxic T-cell response against the antigens present in the DC vaccine. In these studies, adverse effects associated with DC vaccination were uncommon. Most were mild and self-limited and none were serious. 8, 29 Early studies were inadequate in their design and interpretation. Several variables require standardization including the mode of DC preparation, the subtype, maturation and activation status of DCs, the dose and timing interval, the route of administration, and the mode of antigen loading. The experimental basis for the use of DC as a vaccine adjuvant has largely been derived from studies in mice where DC have been cultured from precursors in bone marrow with the help of the recombinant cytokines GM-CSF and IL-4 and may include maturation signals such as recombinant CD40L or synthetic TLR ligands. [30] [31] [32] The culture protocol for the generation of DC determines their capacity to take up and process antigen, migrate to the regional lymph node, and present antigen to naı¨ve T cells in the context of costimulatory molecules and appropriate cytokines. Diverse antigen-loading strategies including synthetic or mixed tumor-derived MHC class I-binding peptides, recombinant or crude tumor cell-derived protein, plasmid DNA, recombinant virus, synthetic or whole tumor-derived RNA, as well as whole tumor cells or tumor cell-derived apoptotic bodies have been evaluated. 10, 11, 33, 34 Currently, the optimal culture protocol and the optimal antigen-loading strategy for DC-based melanoma vaccines are both a matter of intense debate.
In the present study, we compared synthetic peptide and recombinant Adenovirus for antigen loading of cultured DC in the B16 mouse model. Peptide-pulsed DC did not confer significant protection against B16 lung metastases. Flow cytometric detection of CD8 þ T-cell responses with H2-K b pentamers and measurement of in vivo cytotoxicity targeting the OVA aa257-264 peptide epitope demonstrated that Ad-transduced DC stimulated a stronger CTL-response in vivo than peptide-pulsed DC. In agreement with other investigators, we hypothesize that continuous synthesis of antigen by DC is superior to brief peptide-loading where antigen presentation is limited by dissociation of the MHC class I peptide complex. 35 Using a recombinant Ad encoding only the TRP2 aa180-188 peptide epitope attached to EGFP, we show that immunization with Ad-TRP2-transduced DC was clearly superior to TRP2 aa180-188 peptide-pulsed DC. This result also demonstrated that DC-based genetic immunization targeting a single peptide epitope derived from the melanocytic self-antigen TRP2 can effectively promote antimelanoma immunity in vivo. Experiments employing Ad-EGFP-transduced DC pulsed with the synthetic TRP2 aa180-188 peptide ruled out that Adenovirus transduction or expression of EGFP indirectly enhanced the immunogenicity of cultured DC.
The limited efficacy of cultured DC pulsed with the TRP2 aa180-188 peptide epitope may be enhanced by coadministration of immunostimulatory cytokines such as IL-2 12, 36 or by multiple injections of peptide-pulsed DC. 11 As an alternative strategy, Wang et al. 13 attached the TRP2 aa180-188 peptide to the protein transduction domain of HIV TAT, which leads to prolonged antigen To analyze the role of CD4 þ T cells in the effector phase, groups of five C57BL/6 mice were immunized with EGFP.TRP2 aa180-188 and CD4 þ T-cells depleted using an anti-CD4 mAb as described in Materials and methods. Control groups received purified rat IgG. Mice were challenged with 4 Â 10 5 B16 melanoma cells and the lung metastases were evaluated 14 days later. Each dot represents an individual mouse of a single experiment, which was repeated three times with similar results.
presentation by DC. The same technique was also successfully employed using recombinant TRP2 protein and cultured DC. 33 Our results provide one possible explanation for the lack of efficacy in human clinical studies using peptide-pulsed DC and suggest that antigenloading strategies for DC-based melanoma vaccines need to be optimized. As a clinically more attractive alternative, we also demonstrated that direct injection of recombinant Adenovirus can be as effective as administration with cultured DC provided that the TRP2 aa180-188 peptide epitope is attached to an immunogenic helper protein such as EGFP. 15, 37 In our previous studies, we showed that immunization with an Adenovirus encoding full-length murine tyrosinase-related protein 2 (mTRP2) alone is not sufficient to protect mice against metastatic growth of B16 melanoma cells in the lung. 7, 9 Here, we confirmed that CD4 þ T-cell help is required for effective stimulation and expansion of TRP2-specific CD8 þ T cells using CD4 knockout mice. Experiments with depleting anti-CD4 mAb demonstrated that CD4 þ T-helper cells were not required in the effector phase of protective antimelanoma immunity. We believe that linkage of the weakly immunogenic TRP2 peptide with strong CD4 helper epitopes licenses DC in vivo for the stimulation of CD8 þ T cells. This model also explains the absolute requirement for linkage of the helper protein since both MHC class I-and MHC class II-binding peptide epitopes need to be presented by the same DC. 19 The importance of CD4 þ T-cell help for the generation of CD8 þ T-cell effector and memory functions has recently been reappreciated. [38] [39] [40] [41] [42] Furthermore, it has also been shown that CD40 ligation releases DC from control of regulatory T cells. 43 In conclusion, our results help to elucidate the requirements for effective in vivo stimulation of melanoma-specific CD8 þ T cells using cultured DC as a biological adjuvant and support the translation of DCbased genetic melanoma vaccines in future clinical trials.
